DNDi aims to:

  • Complete the development and register two drugs that are effective against both stages of the disease and both subspecies of the parasite (Trypanosoma brucei gambiense (g-HAT) and Trypanosoma brucei rhodesiense (r-HAT).

 

The current sleeping sickness portfolio includes:

 Research

Discovery

SCYX-1330682 & SCYX-1608210 Oxaboroles

Development

Development

Acoziborole (SCYX-7158)
Fexinidazole T.b. rhodesiense

 Implementation

Implementation

Fexinidazole
NECT – Nitfurtimox-Eflornithine Combination Therapy

 

For more details on each project, see DNDi‘s Global Portfolio